<DOC>
	<DOC>NCT00569192</DOC>
	<brief_summary>The purpose of this study is to examine the safety and efficacy of two doses of MAP0010 versus placebo in asthmatic infants and children, 12 months to 8 years of age, over a 12-week treatment period.</brief_summary>
	<brief_title>A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Male or female asthmatic children with mild to moderate persistent asthma. 12 months to 8 years of age. For children age 4 to 8 years: Documented diagnosis of asthma at least 3 months prior to Visit 1, per NIH (EPR3) criteria. For infants age 12 to &lt;48 months old: 2 or more wheezing episodes in past 12 months which lasted &gt; 1 day and affected sleep. AND with at least one major or two minor risk factors. Any other significant childhood illness/abnormality or chronic lung disease Any history of upper or lower respiratory tract infection, within 2 weeks of screening. Any history of acute or severe asthma attack requiring ICU admission or ventilatory support. Use of any corticosteroid, including inhaled, parental, intranasal, or topical corticosteroid within 2 weeks of screening. Any use of oral corticosteroids within 30 days of screening or prolonged use (&gt;10 consecutive days) of oral corticosteroids, within 12 weeks of screening.</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>asthmatic children</keyword>
</DOC>